# EDGAR Filing Document

**Accession Number:** 0001137360
**File Stem:** 0001752724-23-042728
**Filing Date:** 2023-2
**Character Count:** 16502
**Document Hash:** 3dbf96dc236e2dcde5d8095633986f25
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001752724-23-042728.hdr.sgml**: 20230227

**ACCESSION NUMBER**: 0001752724-23-042728

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20221231

**FILED AS OF DATE**: 20230227

**DATE AS OF CHANGE**: 20230227

**PERIOD START**: 20230930

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VanEck ETF Trust
- **CENTRAL INDEX KEY:** 0001137360
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-10325
- **FILM NUMBER:** 23673481

**BUSINESS ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** 212-293-2000

**MAIL ADDRESS:**
- **STREET 1:** 666 THIRD AVENUE, 9TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** VanEck Vectors ETF Trust
- **DATE OF NAME CHANGE:** 20160427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS ETF TRUST
- **DATE OF NAME CHANGE:** 20070312

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MARKET VECTORS TRUST
- **DATE OF NAME CHANGE:** 20050516

## Series and Classes Contracts Data

### VanEck Biotech ETF (Series ID: S000034406)

| Class ID   | Class Name         | Ticker Symbol   |
|:---|:---|:---|
| C000105864 | VanEck Biotech ETF | BBH             |

## Nport-Ex

VANECK BIOTECH ETF

SCHEDULE OF INVESTMENTS

December 31, 2022 (unaudited)

---

| | | |
|:---|:---|:---|
| | **Number<br> of Shares** | **Value** |
| **COMMON STOCKS: 100.2%** |  |  |
| **China: 4.1%** |  |  |
| BeiGene Ltd. (ADR) \* | 92893 | $20430887 |
| **Germany: 4.3%** |  |  |
| BioNTech SE (ADR) | 140873 | 21161942 |
| **Ireland: 3.9%** |  |  |
| ICON Plc (USD) \* | 98205 | 19076321 |
| **Switzerland: 0.8%** |  |  |
| CRISPR Therapeutics AG (USD) \* † | 91759 | 3730003 |
| **United States: 87.1%** |  |  |
| Alnylam Pharmaceuticals, Inc. \* | 91065 | 21641597 |
| Amgen, Inc. | 229727 | 60335499 |
| Argenx SE (ADR) \* | 49482 | 18745266 |
| Biogen, Inc. \* | 87133 | 24128870 |
| BioMarin Pharmaceutical, Inc. \* | 189152 | 19575340 |
| Bio-Techne Corp. | 188807 | 15648324 |
| Charles River Laboratories International, Inc. \* | 61199 | 13335262 |
| Exact Sciences Corp. \* | 194543 | 9631824 |
| Gilead Sciences, Inc. | 504935 | 43348670 |
| Guardant Health, Inc. \* | 83721 | 2277211 |
| Illumina, Inc. \* | 109870 | 22215714 |
| Incyte Corp. \* | 195553 | 15706817 |

---

---

| | | |
|:---|:---|:---|
| | **Number<br> of Shares** | **Value** |
| **United States (continued)** |  |  |
| Intellia Therapeutics, Inc. \* | 92102 | $3213439 |
| IQVIA Holdings, Inc. \* | 122566 | 25112548 |
| Moderna, Inc. \* | 161108 | 28938219 |
| Natera, Inc. \* | 132459 | 5320878 |
| QIAGEN NV \* | 273884 | 13658595 |
| Regeneron Pharmaceuticals, Inc. \* | 35925 | 25919528 |
| Repligen Corp. \* | 60792 | 10292694 |
| Seagen, Inc. \* | 143156 | 18396978 |
| Vertex Pharmaceuticals, Inc. \* | 117692 | 33987096 |
|  |  | 431430369 |
| **Total Common Stocks** <br> (Cost: $498,223,476) |  | 495829522 |
| **SHORT-TERM INVESTMENT HELD AS<br> COLLATERAL FOR SECURITIES ON LOAN: 0.2%** | **SHORT-TERM INVESTMENT HELD AS<br> COLLATERAL FOR SECURITIES ON LOAN: 0.2%** | **SHORT-TERM INVESTMENT HELD AS<br> COLLATERAL FOR SECURITIES ON LOAN: 0.2%** |
| **Money Market Fund: 0.2%**<br> (Cost: $1,210,628) |  |  |
| State Street Navigator Securities Lending Government Money Market Portfolio | 1210628 | 1210628 |
| **Total Investments: 100.4%**<br> (Cost: $499,434,104) |  | 497040150 |
| **Liabilities in excess of other assets: (0.4)%** | **Liabilities in excess of other assets: (0.4)%** | (1814106) |
| **NET ASSETS: 100.0%** |  | $495226044 |

---

------

**Definitions:**

ADR American Depositary Receipt <br> USD United States Dollar

**Footnotes:**

---

| | |
|:---|:---|
| \* | Non-income producing |
| † | Security fully or partially on loan. Total market value of securities on loan is $3,543,501. |

---

---

| | | |
|:---|:---|:---|
| **Summary of Investments by Sector<br> <u>Excluding Collateral for Securities Loaned</u>** | **% of<br> Investments** | **Value** |
| Biotechnology | 75.3% | $374212853 |
| Life Sciences Tools & Services | 24.2 | 119339458 |
| Health Care Services | 0.5 | 2277211 |
|  | 100.0% | $495829522 |

---

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** VanEck ETF Trust

- **b. Investment Company Act file number:** 811-10325

- **c. CIK number of Registrant:** 0001137360

- **d. LEI of Registrant:** 549300ZLFKNTXC51ZN76

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 666 THIRD AVENUE, 9TH FLOOR

  - **City:** NEW YORK

  - **State:** NY

  - **Foreign country:** US

  - **Zip / Postal Code:** 10017

  - **Telephone number:** 212-293-2000

**Item A.2. Information about the Series.**

- **a. Name of Series:** VanEck Biotech ETF

- **b. EDGAR series identifier (if any):** S000034406

- **c. LEI of Series:** 549300PGHG6VYS4R2K51

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2023-09-30

- **b. Date as of which information is reported:** 2022-12-31

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $497043491.72

**Total Liabilities:** $1817447.90

**Net Assets:** $495226043.82

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000105864 | 11.68%               | 6.93%                | -4.32%               |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $-3214978.40             | $52966879.79                               |
| Month 2  | $2385528.99              | $30793291.62                               |
| Month 3  | $13297139.20             | $-37243795.39                              |

### Schedule of Portfolio Investments

| Name                                         | Title                                                                       | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Charles River Laboratories International Inc | Charles River Laboratories International Inc                                | CUSIP: 159864107<br>LEI: 549300BSQ0R4UZ5KX287 | Long             | EC               | CORP              | US        |     61199 | NS      | $13335262.10  | 2.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                  | Alnylam Pharmaceuticals Inc                                                 | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |     91065 | NS      | $21641597.25  | 4.37%             |  |  |  | No            |                  1 | On Loan: No      |
| BioNTech SE                                  | BioNTech SE                                                                 | CUSIP: 09075V102<br>LEI: 894500UZJ5LG1F8J1U58 | Long             | EC               | CORP              | DE        |    140873 | NS      | $21161942.06  | 4.27%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                   | Vertex Pharmaceuticals Inc                                                  | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |    117692 | NS      | $33987095.76  | 6.86%             |  |  |  | No            |                  1 | On Loan: No      |
| Exact Sciences Corp                          | Exact Sciences Corp                                                         | CUSIP: 30063P105<br>LEI: 549300VM3X1FYD4N9Z14 | Long             | EC               | CORP              | US        |    194543 | NS      | $9631823.93   | 1.94%             |  |  |  | No            |                  1 | On Loan: No      |
| Repligen Corp                                | Repligen Corp                                                               | CUSIP: 759916109<br>LEI: 54930006QJ0T5AUO1E71 | Long             | EC               | CORP              | US        |     60792 | NS      | $10292693.52  | 2.08%             |  |  |  | No            |                  1 | On Loan: No      |
| QIAGEN NV                                    | QIAGEN NV                                                                   | CUSIP: 000000000<br>LEI: 54930036WK3GMCN17Z57 | Long             | EC               | CORP              | NL        |    273884 | NS      | $13658595.08  | 2.76%             |  |  |  | No            |                  1 | On Loan: No      |
| BioMarin Pharmaceutical Inc                  | BioMarin Pharmaceutical Inc                                                 | CUSIP: 09061G101<br>LEI: NSLL8ITTRR0J5HEMR848 | Long             | EC               | CORP              | US        |    189152 | NS      | $19575340.48  | 3.95%             |  |  |  | No            |                  1 | On Loan: No      |
| State Street Global Advisors                 | State Street Navigator Securities Lending Government Money Market Portfolio | CUSIP: 857492706<br>LEI: 5493008BJIBKQ5KTIF74 | Long             | STIV             | RF                | US        |   1205902 | NS      | $1205902.50   | 0.24%             |  |  |  | No            |                  1 | On Loan: No      |
| Seagen Inc                                   | Seagen Inc                                                                  | CUSIP: 81181C104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    143156 | NS      | $18396977.56  | 3.71%             |  |  |  | No            |                  1 | On Loan: No      |
| Intellia Therapeutics Inc                    | Intellia Therapeutics Inc                                                   | CUSIP: 45826J105<br>LEI: 5493002T5BCPE5DZC723 | Long             | EC               | CORP              | US        |     92102 | NS      | $3213438.78   | 0.65%             |  |  |  | No            |                  1 | On Loan: No      |
| Biogen Inc                                   | Biogen Inc                                                                  | CUSIP: 09062X103<br>LEI: W8J5WZB5IY3K0NDQT671 | Long             | EC               | CORP              | US        |     87133 | NS      | $24128870.36  | 4.87%             |  |  |  | No            |                  1 | On Loan: No      |
| IQVIA Holdings Inc                           | IQVIA Holdings Inc                                                          | CUSIP: 46266C105<br>LEI: 549300W3R20NM4KQPH86 | Long             | EC               | CORP              | US        |    122566 | NS      | $25112547.74  | 5.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Moderna Inc                                  | Moderna Inc                                                                 | CUSIP: 60770K107<br>LEI: 549300EI6OKH5K5Q2G38 | Long             | EC               | CORP              | US        |    161108 | NS      | $28938218.96  | 5.84%             |  |  |  | No            |                  1 | On Loan: No      |
| CRISPR Therapeutics AG                       | CRISPR Therapeutics AG                                                      | CUSIP: 000000000<br>LEI: 506700O6IRRIQLT3W370 | Long             | EC               | CORP              | CH        |     91759 | NS      | $3730003.35   | 0.75%             |  |  |  | No            |                  1 | On Loan: —       |
| Illumina Inc                                 | Illumina Inc                                                                | CUSIP: 452327109<br>LEI: SQ95QG8SR5Q56LSNF682 | Long             | EC               | CORP              | US        |    109870 | NS      | $22215714.00  | 4.49%             |  |  |  | No            |                  1 | On Loan: No      |
| Guardant Health Inc                          | Guardant Health Inc                                                         | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |     83721 | NS      | $2277211.20   | 0.46%             |  |  |  | No            |                  1 | On Loan: No      |
| Incyte Corp                                  | Incyte Corp                                                                 | CUSIP: 45337C102<br>LEI: 549300Z4WN6JVZ3T4680 | Long             | EC               | CORP              | US        |    195553 | NS      | $15706816.96  | 3.17%             |  |  |  | No            |                  1 | On Loan: No      |
| ICON PLC                                     | ICON PLC                                                                    | CUSIP: 000000000<br>LEI: 6354008SRQGEMC4XFI67 | Long             | EC               | CORP              | IE        |     98205 | NS      | $19076321.25  | 3.85%             |  |  |  | No            |                  1 | On Loan: No      |
| Amgen Inc                                    | Amgen Inc                                                                   | CUSIP: 031162100<br>LEI: 62QBXGPJ34PQ72Z12S66 | Long             | EC               | CORP              | US        |    229727 | NS      | $60335499.28  | 12.18%            |  |  |  | No            |                  1 | On Loan: No      |
| Bio-Techne Corp                              | Bio-Techne Corp                                                             | CUSIP: 09073M104<br>LEI: 54930073RLKQ51TILZ35 | Long             | EC               | CORP              | US        |    188807 | NS      | $15648324.16  | 3.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Argenx SE                                    | Argenx SE                                                                   | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     49482 | NS      | $18745266.06  | 3.79%             |  |  |  | No            |                  1 | On Loan: No      |
| BeiGene Ltd                                  | BeiGene Ltd                                                                 | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | KY        |     92893 | NS      | $20430886.42  | 4.13%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera Inc                                   | Natera Inc                                                                  | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    132459 | NS      | $5320878.03   | 1.07%             |  |  |  | No            |                  1 | On Loan: No      |
| Regeneron Pharmaceuticals Inc                | Regeneron Pharmaceuticals Inc                                               | CUSIP: 75886F107<br>LEI: 549300RCBFWIRX3HYQ56 | Long             | EC               | CORP              | US        |     35925 | NS      | $25919528.25  | 5.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                          | Gilead Sciences Inc                                                         | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    504935 | NS      | $43348669.75  | 8.75%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2023-01-30

**Name of Applicant:** VanEck ETF Trust

**Signature:** James Parker

**Name of Signer:** James Parker

**Title:** Assistant Treasurer